

REMARKS/ARGUMENTS

With entry of the amendment, claims 2, 4, 18, 20 and 22 are pending in this application. Claim 3 is canceled and claims 2 and 4 are amended as set forth in detail herein. Claims 1, 5-17, 19 and 21 were previously canceled. No new matter is added. Applicant reserves the right to pursue any canceled subject matter in a related, co-pending application. In view of the these amendments and the remarks below, reconsideration of the application is respectfully requested.

Claim Amendments

Applicant has amended independent claim 2 to incorporate the element of claim 4, in part. Accordingly, claim 4 has been amended to delete the element incorporated in claim 2.

These amendments are made for purposes of expediting prosecution of the instant application and should not be construed as agreement with or acquiescence to any rejection.

Claim Rejections Under 35 U.S.C. § 112, first paragraph

Claims 2, 18, 20 and 22 stand rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the written description requirement. The Examiner states that the claims are rejected for reasons or record, but limited to the recitation in claim 2 of the phrase, "detecting a suppressive effect on Alzheimer's Disease due to the expression of a nucleic acid of the library."

Applicants respectfully submit that claim 2 is now distinguished by incorporation of the element from claim 4. Namely, claim 2 now specifies that suppressive effect is a suppression of cell death. The rejection was not applied to previous claim 4. Accordingly, the rejection does not apply to claim 2 as now amended and claims 18, 20 and 22 which depend from claim 2.


Therefore, for at least the reasons above, the presently amended claims comply with the written description requirement under 35 U.S.C. § 112, first paragraph. Withdrawal of the present rejection is respectfully requested.

Appln. No. 10/088,699
Amdt. dated January 8, 2008
Reply to Office Action of October 18, 2007

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Eureka Wang". The signature is fluid and cursive, with the first name "Eureka" written in a larger, more prominent script than the last name "Wang".

Eureka Wang
Reg. No. 50,510

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 415-576-0300

JOL;YEW
61248729 v1